Dobutamaine Versus Milrinone in Cardiorenal Syndrome
Status:
Withdrawn
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Heart failure is recognized as one of the most common indications for hospitalization amongst
adults aged >65 years in United States with estimated Medicare cost to be 17 billion or more.
Chronic heart failure is one of the most life threatening cardiovascular disorder thought to
affect nearly six million US population with 600,000 new cases every year. The heart is
responsible for perfusion to all vital organs including kidneys and dysfunction in either
affects both the vital organs. When dysfunction of heart leads to dysfunction of kidneys or
vice versa it is referred to as cardio renal syndrome (CRS). The underlying pathophysiology
for CRS has been poorly understood and considered multifactorial. Worsening renal function
defined as increase in serum creatinine of >0.3mg/dl from baseline occurs in 20-30% of
patients with ADHF and is associated with greater length of hospital stay, hospital
readmission and death. A number of interventions have been used including giving diuretics
which helps in decongestion and helps the heart pump blood more effectively. Sometimes these
therapies are not effective and may even lead to worsening of renal function. In such cases ,
inotrope agents which increase the contractility of the heart have been used to help pump
more blood to vital organs. There have been very few trials assessing the efficacy of these
agents for improving kidney function .The investigators aim to assess the renal recovery with
two such agents - dobutamine and milrinone in patients with cardiorenal syndrome who are
coming with acute decompensated heart failure